Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation (double mutant) in non-small-cell lung cancer (NSCLC).
Merck & Co. revealed the structure of an orally active and potent proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitor macrocyclic peptide, MK-0616, which is being developed for the potential treatment of hypercholesterolemia and atherosclerosis.
A team of researchers from Harvard University has developed a suite of Escherichia coli Nissle 1917 (EcN), named PRObiotic type 3 secretion E. coli therapeutic (PROT3ECT), engineered to secrete a TNF-α nanobody directly into the gut to reduce inflammation in a chemically induced inflammatory bowel disease (IBD) mouse model.
Contrary to current opinion, genomic instability is not the origin of cancer in patients with short telomere syndromes (STSs), researchers from the Johns Hopkins University School of Medicine reported April 2, 2023, in Cancer Cell. Instead, short telomeres appeared to cause memory T-cell dysfunction that increased the risk of a small number of tumor types in individuals with STS. Such syndromes can cause premature aging of different physiological systems.
Gilead Sciences Inc. has divulged thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among others.
Biomea Fusion Inc. has described GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer, osteoporosis, systemic lupus erythematosus, immunological and inflammatory disorders.
Medshine Discovery Inc. has identified acrylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
RSS
